Findings

What do systematic reviews say?

34 questions · 34 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 17.6%GRADE not reported 14 · 41.2%Very low 11 · 32.4%Low 3 · 8.8%Moderate 0 · 0%High 0 · 0%

Deferasirox vs deferiprone

Responder analysis · people with transfusion‐dependent thalassemia

The review found no eligible studies for this question.

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs combined deferasirox and deferiprone

Mortality at any time point · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

Responder analysis · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

Serum ferritin (ng/mL) · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

LIC · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

Satisfaction with treatment · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

Adherence · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs combined deferasirox and deferiprone

AE: Serum creatinine increase · people with transfusion‐dependent thalassemia

1 finding from 1 review

Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Deferasirox vs deferiprone (DFO)

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs deferiprone (DFO)

QoL

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Deferasirox vs deferiprone (DFO)

Adherence to iron chelation therapy (%, SD)

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 452 participants
Very low

Deferasirox vs deferiprone (DFO)

SAEs ‐ thalassaemia‐related SAEs

It is very uncertain whether summary of findings: Comparison 2 ‐ deferasirox (DFX) changes SAEs Thalassaemia‐related SAEs compared with deferiprone (DFO) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 0.95 [0.41, 2.17]
2 studies · 247 participants
Very low

Deferasirox vs deferiprone (DFO)

SAEs ‐ SCD‐related SAEs

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 195 participants
Very low

Deferasirox vs deferiprone (DFO)

All‐cause mortality

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
0.96 [0.06, 15.42]
2 studies · 240 participants
Very low